Advisers to the Centers for Disease Control and Prevention on April 16 recommended that the agency expand the availability of vaccines against the respiratory syncytial virus, or RSV.
Adults with at least one risk factor for RSV should be able to receive a vaccine, the Advisory Committee on Immunization Practices said in a 14–0 vote, with one member abstaining.
“What’s swaying me is there clearly are people in that 50 to 59 year sort of age group—for example lung transplant patients, hematopoietic stem cell transplant patients—that would clearly benefit from having access to this vaccine,” Dr. Jane Zucker, one of the members who voted in favor of expanding access, said after the panel was presented with data on the RSV vaccines during a meeting….